Q4 2024 EPS Estimates for Charles River Laboratories International, Inc. (NYSE:CRL) Raised by Analyst

Charles River Laboratories International, Inc. (NYSE:CRL) – Stock analysts at Zacks Research lifted their Q4 2024 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a research note issued on Monday, April 29th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $3.21 for the quarter, up from their previous forecast of $3.20. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $11.01 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q4 2025 earnings at $3.33 EPS.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. Charles River Laboratories International’s quarterly revenue was down 7.9% on a year-over-year basis. During the same period last year, the company earned $2.98 earnings per share.

Several other equities research analysts have also recently commented on CRL. Citigroup boosted their price target on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a research report on Thursday, February 15th. Evercore ISI increased their price target on Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a research report on Thursday, February 15th. Guggenheim lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Finally, Argus raised their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, March 18th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $253.23.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $229.00 on Tuesday. Charles River Laboratories International has a 12 month low of $161.65 and a 12 month high of $275.00. The company’s fifty day simple moving average is $253.22 and its 200-day simple moving average is $223.32. The firm has a market cap of $11.80 billion, a PE ratio of 24.86, a P/E/G ratio of 1.79 and a beta of 1.40. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73.

Insiders Place Their Bets

In other news, VP William D. Barbo sold 4,050 shares of the stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the transaction, the vice president now directly owns 22,879 shares of the company’s stock, valued at $5,685,431.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Victoria L. Creamer sold 5,000 shares of Charles River Laboratories International stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the sale, the executive vice president now owns 13,550 shares of the company’s stock, valued at $3,437,635. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares in the company, valued at $5,685,431.50. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock valued at $3,693,663 over the last ninety days. 1.30% of the stock is currently owned by company insiders.

Institutional Trading of Charles River Laboratories International

Hedge funds and other institutional investors have recently bought and sold shares of the business. VisionPoint Advisory Group LLC increased its holdings in shares of Charles River Laboratories International by 105.7% during the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after purchasing an additional 74 shares during the period. Headlands Technologies LLC bought a new position in Charles River Laboratories International during the 3rd quarter worth $37,000. Operose Advisors LLC acquired a new position in Charles River Laboratories International in the 3rd quarter valued at $42,000. Venturi Wealth Management LLC lifted its position in shares of Charles River Laboratories International by 74.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock valued at $51,000 after acquiring an additional 112 shares during the period. Finally, Brown Brothers Harriman & Co. grew its holdings in shares of Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after purchasing an additional 95 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).